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Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer;
however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of
death within a year. Recently, the daily continuous administration of chemotherapy in low doses – called metronomic
chemotherapy (MC) – has been shown to inhibit primary tumor growth and delay metastases in several tumor types;
however, its use as a single therapy is still in question due to its moderate therapeutic benefit. Here, we show that the
combination of weekly gemcitabine with MC of the same drug delays tumor regrowth and inhibits metastasis in mice
implanted orthotopically with pancreatic tumors. We further demonstrate that weekly gemcitabine, but not continuous
MC gemcitabine or the combination of the two drug regimens, promotes rebound myeloid-derived suppressor cell
(MDSC) mobilization and increases angiogenesis in this tumor model. Furthermore, Bv8 is highly expressed in MDSCs
colonizingpancreatic tumors inmice treatedwithweekly gemcitabine compared toMCgemcitabineor the combination
of the two regimens. Blocking Bv8 with antibodies in weekly gemcitabine-treatedmice results in a significant reduction
in tumor regrowth, angiogenesis, and metastasis. Overall, our results suggest that pro-tumorigenic effects induced by
weekly gemcitabine aremediated in part byMDSCs expressing Bv8. Therefore, both Bv8 inhibition andMCcanbe used
as legitimate 'add-on' treatments for preventing post-chemotherapy pancreatic cancer recurrence, progression, and
metastasis following weekly gemcitabine therapy.
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Pancreatic ductal adenocarcinoma (PDA) is one of the most
aggressive human neoplasms exhibiting extremely poor prognosis
with a 5-year survival rate of b5% in an unresectable disease [1]. In
contrast to several other malignancies, pancreatic cancer is highly
resistant to chemotherapy and targeted therapy. The molecular
mechanisms that determine treatment resistance are poorly under-
stood, but it is clear that microenvironmental elements such as
fibrosis and decreased blood supply with relative hypoxia play a role in
treatment failure [2].
The administration of certain chemotherapy drugs at the
maximum tolerated dose (MTD) may result in an acute mobilization
of bone marrow–derived proangiogenic cells to the treated tumor site
[3]. Such a mobilization may promote tumor regrowth, further
refractoriness to therapy, induce angiogenesis, and even accelerate
metastasis [4–6]. However, metronomic chemotherapy (MC)
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(sometimes even on a daily basis) has been shown to inhibitmetastases and
primary tumor growth of several tumor types including pancreatic cancer
[7,8]. In addition, MC has been shown to limit toxicity, chemoresistance
effects, and poor long-term efficacy sometimes seen after MTD
chemotherapy alone [9]. Initially, the mechanistic basis for the activity
ofMCwas believed to be antiangiogenic by nature, through a direct killing
of endothelial cells in the tumor vasculature [10], the suppression of bone
marrow–derived endothelial progenitors [11], or the release of endogenous
antiangiogenic factors [12]. However, it seems that additional therapeutic
effects of MC in the microenvironment of the poorly vascularized PDA is
not fully understood, especially when antiangiogenic drug therapy failed to
improve therapy in this malignancy [13]. Thus, other mechanisms may
account for the activity of MC in PDAs.
One of the major contributors to PDA growth is the presence of
CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) in the
complex tumor microenvironment [14]. MDSCs secrete many factors
that directly contribute to tumor growth, among them prokineticin 2
(PK2/Bv8) that binds to the two highly related G protein–coupled
receptors referred to as PKR1 and PKR2. PK2/Bv8 production by
CD11b+Gr1+ myeloid cells can lead to a positive feedback loop, with
enhanced differentiation of MDSCs into macrophages, as well as
increasedmobilization of these cells from the bonemarrow into the blood
stream [14]. These macrophages infiltrating the tumor microenviron-
ment secrete PK2/Bv8, leading to increased proliferation and migration
of endothelial cells, increased pro-inflammatory cytokines interleukin
(IL)-1β and IL-12, and decreased anti-inflammatory cytokines IL-4 and
IL-10 [15]. Interestingly, the changes in the cytokine profile of the tumor
microenvironment were found also following MTD chemotherapy and
are probably ameliorated with the use of metronomic scheduling [16]. In
addition, our previous studies indicated that bone marrow–derived
proangiogenic cells homing to the MTD chemotherapy–treated tumor
site promote angiogenesis and accelerate metastasis due in part to the up-
regulation of several growth factors and cytokines [4,5]. This pro-
tumorigenic effect found after MTD chemotherapy was abrogated when
bolus injection of chemotherapy was followed by MC chemotherapy of
the same drug [17]. This raises the question of whether the concomitant
administration ofMTD chemotherapy followed byMCmay increase the
therapeutic efficacy of PDA treatment.
In this study, we investigated the hypothesis that MDSC-derived
Bv8 plays a critical role in the resistance of PDA to MTD
gemcitabine. Our results show that MTD gemcitabine markedly
increased the mobilization and homing of MDSC-derived Bv8 to the
tumor site. The elimination of such cells by MC or anti-Bv8
antibodies markedly increased the therapeutic efficacy of gemcitabine
treatment in orthotopic metastatic models of PDA.
Materials and Methods
Tumor Models and Cell Lines
Human Panc-1 and murine Panc-02 pancreatic adenocarcinoma
cells obtained from the American Type Culture Collection (ATCC,
Manassas, VA) were passed in culture for no more than 4 months after
being thawed from authentic stocks. Cells (5 × 106) stably transfected
with luciferase were mixed in Matrigel (BD Biosciences, San Jose, CA)
and were injected transperitoneally into the head of the pancreas of 6-
week-old female Severe Combined Immunodeficiency (SCID) (for
Panc-1) or C57Bl/6 (for Panc-02) mice (Harlan, Jerusalem, Israel) after
incision of the skin and fixation of the pancreas. Tumor size was assessedregularly with in vivo imaging system (IVIS) as indicated below. One
week after tumor implantation, treatment was initiated according to
the schedule and regimen indicated in Supplemental Figure 1, unless
indicated otherwise. Mice were randomly grouped before therapy (n =
3-5 per group, unless indicated otherwise).
Drugs and Concentrations
Gemcitabine hydrochloride (Lilly France S.A.S., Fegersheim,
France) was administered intraperitoneally as a single bolus injection
on a weekly basis at a dose of 500 mg/kg (representing an MTD
regimen) or daily at a dose of 3.3 mg/kg representing an MC
regimen. In the weekly and MC combined therapy regimens, a
reduced dose of weekly gemcitabine was used (375 mg/kg) to avoid
major toxicities. Anti-Bv8, a hamster anti-mouse Bv8 monoclonal
antibody (mAb 2D3, kindly provided by Genentech, San Francisco,
CA), was administered twice weekly at a dose of 5 mg/kg for 2 weeks
in C57Bl/6 mice (for Panc-02) to avoid neutralization of the
antibodies by the immune system as previously documented [18] and
for 4 weeks in SCID mice (for Panc-1). In some experiments, after
21 days of therapy, some of the mice in each group were sacrificed
and tumor, bone marrow, and peripheral blood were analyzed.
Animal weight was monitored twice a week during the course of
treatment. In some experiments, as indicated in the text, a hamster
anti-mouse monoclonal antibody was used as a control antibody
(Jackson ImmunoResearch Europe, Newmarket, UK), administered
in a dose of 5 mg/kg every 2 weeks.
Live Animal Imaging
Bioluminescent imaging of the luciferase-expressing tumors was
performed with a highly sensitive, cooled charge coupled device (CCD)
camera mounted in a light-tight specimen box (IVIS; Xenogen Corp.,
Waltham, MA). Briefly, mice were injected intraperitoneally with
substrate D-luciferin at 150 mg/kg, and after an 8-minute interval, they
were anesthetized using isoflurane. Mice were then placed onto the
warmed stage inside the light-tight camera box, with continuous
exposure to isoflurane (EZAnesthesia, Palmer, PA) for maintenance of
anesthesia. The mice were imaged for 2 minutes. Light emitted from
the bioluminescent cells was detected by the IVIS camera system with
images quantified for tumor burden using a log-scale color range set at
5 × 104 to 1 × 107 and measurement of total photon counts per second
(photons per second) using Living Image software (Xenogen).
Animals were also imaged by magnetic resonance imaging (MRI)
using a dedicated whole body mouse coil in a high-field (1 T) small
animal scanner (M2 Compact High-Performance MRI Platform;
Aspect, Toronto, Canada). The mice were continuously supplied with
2% isoflurane in air for anesthetization. Animals' respiration rate and
body temperature were monitored throughout the entire imaging
procedure. Gadolinium enhancement was used by intraperitoneal
injection of 50 μl of 0.5 M MultiHance (Bracco S.p.A., Milan, Italy).
Flow Cytometry Acquisition and Analysis
Blood or cell suspensions were quantitated for MDSCs, as
described previously [19]. Briefly, blood was obtained from mice by
retro-orbital sinus bleed and was collected in EDTA tubes. Tumors
were removed from the mice and prepared as single-cell suspensions
as previously described [4]. Cells were immunostained for
MDSCs using Gr1+/CD11b+ surface markers. All antibodies were
purchased from BD Biosciences or BioLegend (San Diego, CA). The
experiments were performed on Cyan-ADP flow cytometer
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Version 4.3 (Beckman Coulter).
Quantitation and Visualization of Tissue Hypoxia, Vessel
Perfusion, and Microvessel Density
Tissue processing and immunohistochemistry were performed as
described previously [31]. Briefly, blood vessel perfusion and hypoxia
were analyzed in tumor cryosections (10 to 12 μm) using the DNA-
binding dye Hoechst 33342 (40 mg/kg; Sigma-Aldrich, Rehovot, Israel)
and pimonidazole hydrochloride (60 mg/kg; Natural Pharmacia Inter-
national Inc., Burlington, MA), respectively, according to the manufac-
turers' instructions. Blood vessels were immunostained with anti-CD31
antibodies, an endothelial cell–specific antibody (1:200 ratio; BD
Biosciences), and the number of vessel structures per field was counted
and plotted (at least five fields per tumor, n N 20 fields per group).
Hypoxia and perfusion were quantitated from micrographs by analyzing
the number of positive pixels from the total pixels using Photoshop
CS2 Version 2 software (Adobe Systems, San Jose, CA). Tumor sections
were visualized under Leica CTR 6000 microscope (Leica Microsystems,
Wetzlar, Germany) using the Leica Application Suite Version 3.
Bv8 mRNA Expression Analysis by Reverse
Transcription–Polymerase Chain Reaction
RNA was extracted from tumors using the RNeasy Mini Kit
(Quagen Inc., Valencia, CA) and subsequently converted into cDNA
by reverse transcriptase (Promega Corporation, Madison, WI). A total
volume of 20 μl containing 300 ng of total RNA template and 10 μl
of Power CYBR Green Master Mix (Applied Biosystems, Modiin,
Israel) was prepared. Reactions were run on a 7000 Real-Time PCR
System (Applied Biosystems). The amounts of target genes were
determined from the comparative threshold cycle (CT) method.
Expression level of Bv8 gene was further quantified against the house-
keeping HPRT gene using the same treatment and expressed as 2−
ΔCT(ΔCT of target gene−CT of HPRT). The primer sequences were
given as follows: for mouse Bv8 forward, GCATGACAGGAGT
CATCATTTT; reverse, AAATGGCAGGATATCAGGAAA; for
mouse HPRT forward, ATGTTCCAGTATGACTCCACTCACG;
reverse, GAAGACACCAGTAGACTCCACGACA.
Invasion and Migration Assays
The invasion andmigration properties of Panc-1 and Panc-02 cells in
response to plasma of mice treated with all treatment regimens or
treatment combinations, as indicated above, were evaluated in
fibronectin and Matrigel-coated Boyden chambers for migration and
invasion, respectively, using a previously described protocol [4]. Briefly,
serum-starved cells (2 × 105 cells in 0.2 ml medium) were added to a
filter coated with 10 μl of fibronectin or 50 μl of Matrigel (Biological
Industries, Beit Haemek, Israel and BD Biosciences, Israel, respectively).
The lower compartment was filled with Dulbecco's modified Eagle's
medium that contained 10% plasma obtained from mice 24 hours or
7 days after they were treated with gemcitabine and/or anti-Bv8
antibodies, as indicated in the text. After 4 and 12 hours, respectively,
the cells that migrated to the bottom filter were stained with crystal violet
and counted under an inverted microscope (Leica DM IL LED) per
×100 objective field. All experiments were performed in triplicate.
Statistical Analysis
Data are expressed as means ± SD. The statistical significance of
differences was assessed by one-way analysis of variance, followed byNewman-Keuls ad hoc statistical test using GraphPad Prism 4 software
(La Jolla, CA). Differences between all groups were compared with each
other and were considered significant at values below 0.05.Results
Pancreatic Tumor-Bearing Mice Treated with MC
Regimen Exhibit Controlled Tumor Growth and Reduced
Metastatic Spread
The potential role of MC to delay tumor growth has been shown in
several preclinical models as well as in clinical studies [8,20–22]. Here,
we sought to evaluate the possible therapeutic effect of MC in mice
bearing orthotopic metastatic pancreatic adenocarcinoma, in compar-
ison to the conventional weekly gemcitabine therapy at the MTD. To
this end, Panc-02 tumor cells tagged with luciferase were implanted
orthotopically into the pancreas of 6-week-old C57Bl/6 mice. A week
later, treatment with weekly gemcitabine, MC gemcitabine, or the
combination of the two regimens was initiated according to the
schedule and doses described in Supplemental Figure 1 and Materials
and Methods section. Tumor growth was assessed using IVIS as
described previously [23]. The results in Figure 1 (A–C) demonstrate
that while treatment with weekly gemcitabine improved therapy
outcome following 1 week of therapy, rapid tumor regrowth was
subsequently observed, and no therapeutic benefit was observed over
time despite the continuous treatment protocol. In contrast, treatment
with either MC gemcitabine or the combination of weekly and MC
gemcitabine resulted in suppressed tumor growth during the treatment
period. Consistently, mice treated with the combined regimen survived
longer than all of the other treatment regimens (Figure 1C). Similar
results were observed in Panc-1–bearing SCID mice (Supplemental
Figure 2). However, we must note the high toxicity profile in the
combination therapy–treated mice (data not shown).
Next, we used MRI technology to evaluate metastatic spread in live
mice 28 days after receiving the different therapy regimens. Metastatic
spread was found in the abdominal cavity, digestive system, and
sometimes in the liver, in control untreated mice, as well as in all
treatment regimens although not to the same extent (Figure 1D). Mice
were sacrificed at end point, and metastases were spotted and counted in
different anatomic areas including the gastrointestinal (GI) tract, stomach,
greater omentum, hepatic port, and liver. As seen in Table 1, mice treated
with the combination therapy regimen and, to a lesser extent, with MC
regimen exhibited a lower number of metastases in the different organs,
when compared to weekly gemcitabine-treated or untreated control mice.
Overall, these results indicate that the combination of weekly and MC
gemcitabine improves therapy outcome by delaying primary tumor
regrowth and reducing metastatic spread.
Host Response to Weekly Gemcitabine Promotes Tumor Cell
Migration and Rebound MDSC Mobilization
Our previous studies have shown that plasma obtained from mice
treated with chemotherapy induces tumor cell invasion indicating a
pro-tumorigenic host effect in response to chemotherapy [4]. The
increased metastatic spread found following weekly gemcitabine
therapy prompted us to investigate the host response in the different
treatment regimens. Specifically, we asked whether plasma from mice
treated with gemcitabine in the different regimens differentially affect
tumor cell invasion. To this end, Panc-1 and Panc-02 tumor cells were
placed on a Boyden chamber coated with Matrigel. Dulbecco's
modified Eagle's medium supplemented with 10% plasma from non–
Figure 1. The combination ofweekly and daily gemcitabine therapy improves therapeutic outcome inmice bearing pancreatic tumors. Eight-
week-old C57Bl/6 mice were implanted orthotopically with 5 × 106 Panc-02 cells stably transfected with luciferase. After 7 days, they were
either left untreated (Control) or treatedwith gemcitabine in the following regimens:maximum tolerated dose administeredweekly (MTD-G),
metronomic dose administered daily (MC-G), or the combination of the two regimens (COMB-G) as described in FigureW1. (A) Tumor growth
was evaluatedover timeusing IVIS following injectionwith luciferin aspreviously described [23]. (B) Tumorgrowthwasquantified by counting
the number of photons collected at 8 minutes after luciferin injection when compared to their pre-treatment values. *, P b .05 when
compared to pre-treated control. (C) Survival of mice from all groups was plotted using the Kaplan-Meier curve. (D) In a parallel experiment,
28 days following the different gemcitabine regimens,micewere imaged byMRI Spectra 1T. Non–tumor-bearingmice (NBT) ormice bearing
tumors on day 5 pre-treatment (Tumor 5d) were also imaged for comparison. Representative images are shown.
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regimens was placed at the bottom of the chamber. As shown in
Figure 2A, invasion of Panc-1 and Panc-02 cells to the bottom of the
chamber was significantly increased in the presence of plasma frommiceTable 1. Spread of macroscopic tumor lesions in Panc-02–bearing mice following treatment with
gemcitabine in different drug regimens. Mice were implanted orthotopically with Panc-02 tumors
and subsequently treated with gemcitabine in the following regimens: maximum tolerated dose
administered weekly (MTD-G), metronomic dose administered daily (MC-G), or the combination
of the two regimens (COMB-G) as described in Figure W1. At end point, the mice were sacrificed
and macrometastases in the, GI track, stomach, greater omentum, hepatic ports, and liver were














Control 13 1074 ± 662 11/13 (85%) 13/13 (100%) 7/13 (54%) 2/13 (15%)
MTD-G 13 785 ± 544 9/13 (69%) 13/13 (100%) 5/13 (38%) 5/13 (38%)
MC-G 13 619 ± 490 6/13 (46%) 11/13 (84%) 3/13 (23%) 0/13 (0%)
COMB-G 13 245 ± 189 4/13 (30%) 8/13 (61%) 1/13 (8%) 0/13 (0%)treated with weekly gemcitabine when compared to control,MC, or the
combination of the two regimens. It should be noted that the tumor
cells exhibited similar migration properties in the presence of plasma
from all treatment regimens (data not shown). We next assessed
whether rebound angiogenesis sometimes seen between successive drug
intervals [6] may also account for tumor regrowth andmetastatic spread
found following weekly gemcitabine. To test this, we focused on
MDSCs because they have been shown to promote angiogenesis in
pancreatic tumors [24]. In addition, gemcitabine has already been
reported as a drug that does not affect circulating endothelial progenitor
cells known to directly support tumor angiogenesis [3,25]. To test
MDSC mobilization, non–tumor-bearing mice were treated with the
drug regimens indicated above and the level of MDSCs in daily drawn
blood samples was evaluated by flow cytometry. Weekly gemcitabine
caused an immediate suppression in MDSC levels followed by a rapid
and significant mobilization that returned back to normal levels by day
10. In contrast, no significant changes in the number of MDSCs were
observed with the other treatment regimens (Figure 2B).
Next, we assessed the number of MDSCs in the peripheral blood,
bone marrow, and tumors of pancreatic tumor-bearing mice treated
Figure 2. Weekly gemcitabine induces host pro-tumorigenic effects that promote tumor cell invasion and increase the number of MDSCs.
Non–tumor-bearing C57Bl/6micewere either untreated (Control) or treatedwith gemcitabine administeredweekly at themaximum tolerated
dose (MTD-G), daily at a metronomic dose (MC-G), or in a combination of the two regimens (COMB-G). (A) Plasmawas drawn after 7 days of
therapy and used in a Boyden chamber assay for the assessment of Panc-1 and Panc-02 tumor cell invasion as described in theMaterials and
Methods section. Cells migrating to the bottom of the filter were counted and plotted. (B) In a parallel experiment, blood frommice treated
with the different gemcitabine regimens was sampled on a daily basis for 10 sequential days. The number of MDSCs in the peripheral blood
was evaluated by flow cytometry. (C) In a separate experiment, mice bearing orthotopic pancreatic tumors were treated with the different
gemcitabine treatment regimens as indicated above. After 21 days, blood was drawn by cardiac puncture, bone marrow cells were flushed
from the bonemarrow, and tumorswere removed. The percentage ofMDSCs in the blood, bonemarrow, and tumor sampleswas assessed
by flow cytometry. The MDSC count in non–tumor-bearing mice is shown in the inset. *, P b .05; **, .01 N P N .001; ***, P b .001.
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increased in the peripheral blood and tumors of pancreatic tumor-
bearing mice on day 21 after weekly gemcitabine therapy. Interestingly,
a significant decrease in the number of MDSCs was observed in mice
treated with the combination of the two drug regimens in the blood
(Figure 2C). Overall, these results suggest that, in response to weekly
gemcitabine treatment, the host promotes tumor cell invasion as well as
MDSCmobilization and tumor homing, which could account for rapid
regrowth and metastasis. In contrast, the addition of MC to weekly
gemcitabine could inhibit these pro-tumorigenic properties.
Bv8 Is Highly Expressed in MDSCs in Mice Treated with
Weekly Gemcitabine
Bv8 has been shown to promote angiogenesis and tumor growth [14].
Because it is abundantly expressed in MDSCs [26], which we showed
were mobilized by weekly gemcitabine, we asked whether blocking Bv8
could improve weekly gemcitabine therapy outcome. We assessed the
relative expression of Bv8 in peripheral blood, bone marrow, andMDSCs inmice treated with the different treatment regimens to identify
whether other cell types besides MDSCs express Bv8 and whether the
expression of Bv8 is related to the host effects in response to the therapy.
We found that the levels of Bv8 were highly elevated specifically in
MDSCs of non–tumor-bearing mice treated with weekly gemcitabine
when compared to all other treatment regimens (Figure 3A). Then, we
asked whether mice bearing pancreatic tumors also exhibit elevated levels
of Bv8 in MDSCs both in the peripheral blood and in the tumor,
following any of the treatment regimens. The results in Figure 3B show
that Bv8 is highly expressed specifically in MDSCs isolated from the
peripheral blood or tumors only inmice treated with weekly gemcitabine
when compared to all other treatment regimens. Overall, these results
suggest that the host response to weekly gemcitabine therapy induces
Bv8 expression specifically in MDSCs.
Next, because MDSCs and Bv8 have been shown to promote
angiogenesis and tumor growth, especially in mice treated with
antiangiogenic drugs [27], we investigated the effect of MDSCs on
angiogenesis in pancreatic tumors following treatment with
Figure 3.Weekly gemcitabine therapy increases Bv8 expression and tumor angiogenesis. (A) Non–tumor-bearing C57Bl/6 mice were either
untreated (Control) or treated with gemcitabine administered weekly at the maximum tolerated dose (MTD-G), daily at a metronomic dose
(MC-G), or in a combination of the two regimens (COMB-G). Seven days after treatment initiation, mice were sacrificed. The level of Bv8
mRNAwas assessed by reverse transcription–polymerase chain reaction in the peripheral blood (PBL), bonemarrow cells (BM), andMDSCs
(Gr1+CD11b+) 7 days after treatment initiation. (B) Pancreatic tumor (Panc-02) bearing mice were treated with the different gemcitabine
regimens as indicated above. After 21 days of treatment, blood was drawn by cardiac puncture, mice were sacrificed, and tumors were
removed. The relative expression of Bv8 mRNA was assessed by reverse transcription–polymerase chain reaction on sorted MDSCs from
both peripheral blood and tumor cells thatwere prepared as single cell suspensions. (C) Left panel: Tumor sections from all treatment groups
werestained forCD31 representingendothelial cells (in red), hypoxia usinghypoxic probe (in green), andHoechst for assessment of perfusion
(in blue). Right panel: To visualize MDSCs within the tumor, the sections were immunostained with anti-Gr1 (red) and anti-CD11b (green)
antibodies. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue); scale bar, 200 μm.Microvessel density, the ratio of hypoxia
over perfusion, and cells expressing both Gr1 and CD11b were quantified from the stained tumor sections from all groups (n N 20 fields per
group) and subsequently plotted. *, P b .05; **, .01 N P N .001; ***, P b .001.
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Panc-02 tumors were treated with weekly gemcitabine, MC daily
gemcitabine, or the combination of the two regimens. On day 21 post
treatment, the mice were sacrificed and the pancreas was analyzed for
hypoxia, perfusion, and microvessel density to assess the nature of
angiogenesis. The results in Figure 3C show that treatment with weekly
gemcitabine resulted in increased colonization ofMDSCs in the tumor,
consistent with the flow cytometry results shown in Figure 2C. In
addition, tumors from mice treated with weekly gemcitabine were
relatively more perfused and less hypoxic than tumors treated with MC
gemcitabine or the combination of the two regimens. Overall, these
results further suggest that the increased colonization of Bv8-expressing
MDSCs in pancreatic tumors results in highly perfused tumors that
could explain their rapid regrowth following weekly gemcitabine
therapy. These effects can be blocked by the addition of MC
gemcitabine toweeklyMTDgemcitabine, improving therapy outcome.Anti-Bv8 Antibodies Block Weekly Gemcitabine-Induced
Rebound MDSCs and Improve Therapy Outcome
The high expression of Bv8 in MDSCs, which colonize tumors in
mice treated with weekly gemcitabine, and their impact on induction
of angiogenesis further prompted us to test whether blocking Bv8 in
the weekly gemcitabine treatment regimen can improve therapy
outcome by delaying primary tumor regrowth and metastatic spread.
To this end, mice were implanted with Panc-02 cells, and a week
later, treatment with weekly gemcitabine with or without anti-Bv8
antibody was initiated. As a control for Bv8 antibody administration,
a hamster anti-mouse monoclonal antibody was used. Bv8 was
administered only for 2 weeks to reduce the immunologic response of
the host to the drug. The results in Figure 4A show that mice treated
with weekly gemcitabine in combination with Bv8 antibody
exhibited a significant reduction in primary tumor growth when
compared to all other treatment groups. We should note that anti-
Figure 4. Anti-Bv8 antibodies block MDSC mobilization and tumor homing. Eight-week-old C57Bl/6 mice were orthotopically implanted with
Panc-02 tumor cells (5 × 106 cells/100 μl). After 7 days, treatment with weekly gemcitabine (MTD-G) with or without anti-Bv8 antibody (ABv8)
administered twice weekly for 2 weeks was initiated. (A) Tumor growth was assessed by IVIS. Representative images are shown in the upper
panel. Tumor sizewas quantified by detecting photon intensity (lower panel). (B) In a different experiment, non–tumor-bearingmicewere treated
with the drug combinations as indicated above, and blood was sampled daily (through retro-orbital sinus bleed) for the evaluation of MDSC
number in peripheral bloodby flowcytometry. (C) Tumor-bearingmice from (A)were treated as indicated above, and14 days after treatmentwas
initiated,micewere sacrificed and tumorswere removed. Half of each tumorwas prepared as a single cell suspension for the assessment of the
percentage ofMDSCs in the tumors by flowcytometry. (D) The other half of the tumorwas sectioned and stainedwith anti-CD31 antibodies (red)
to detect endothelial cells, hypoxic probe (green) to detect hypoxia, and Hoechst (blue) to assess perfusion (upper micrographs). To visualize
MDSCswithin the tumor, the sectionswere immunostainedwith anti-Gr1 (red) and anti-CD11b (green) antibodies.Nucleiwere stainedwithDAPI
(blue; lower micrographs); scale bar, 200 μm.Microvessel density, the ratio of hypoxia over perfusion in tumors, and cells expressing both Gr1
and CD11bwere quantified in tumor sections from all groups (n N 20 fields per group) and subsequently plotted. *, P b .05; **, .01 N P N .001;
***, P b .001.
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therapy outcome. Next, we evaluated the number of MDSCs in the
peripheral blood of these mice during the therapy and found that the
rebound MDSC mobilization found following weekly gemcitabine
was markedly and significantly reduced when the treatment included
anti-Bv8 therapy (Figure 4B). The administration of isotype-control
antibody to non–tumor-bearing mice did not significantly alter the
number of MDSCs when compared to control untreated mice during
the treatment period (Figure W3A). As a result, the number of
MDSCs colonizing the treated tumors was also reduced when the
treatment was combined with anti-Bv8 antibodies as seen by flow
cytometry and immunofluorescent staining analysis (Figure 4, C–D).
Parallel results of primary tumor growth were also observed in SCID
mice bearing Panc-1 tumors. However, the anti-Bv8 antibodytherapy was as good as anti-Bv8 combined with weekly gemcitabine,
indicating its high efficacy in blocking tumor growth in this model
(Supplemental Figure 4). It should be noted that no significant differences
in tumor growth, microvessel density, and MDSC colonization of
Panc-02 tumors were observed between control-untreated mice
and mice treated with the isotype-control monoclonal antibody
(Supplemental Figure 3B-C). In terms of metastasis, we sought to
determine the effect of anti-Bv8 on the invasion of tumor cells following
gemcitabine therapy. To this end, 8-week-old non–tumor-bearing
C57Bl/6 mice were treated with 500 mg/kg gemcitabine (MTD),
5 mg/kg anti-Bv8 antibodies, or the combination of the two drugs. After
24 hours, plasma was collected and used to assess the invasion properties
of Panc-1 and Panc-02 cells. The results in Figure 5A show that plasma
from mice treated with MTD gemcitabine induced tumor cell invasion
Figure 5. Anti-Bv8 antibodies improve therapy outcome. (A) Eight-week-old non–tumor-bearing C57Bl/6 mice were treated with
gemcitabine (500 mg/kg, MTD-G) with or without anti-Bv8 antibody (5 mg/kg, A-Bv8). After 24 hours, blood was drawn by cardiac
puncture and plasma was separated and used in a Boyden chamber assay for the assessment of Panc-1 and Panc-02 tumor cell invasion
as described in the Materials and Methods section. Cells migrating to the bottom of the filter were counted and plotted. (B) Eight-week-
old C57Bl/6 mice were orthotopically implanted with Panc-02 tumor cells (5 × 106 cells/100 μl). After 7 days, treatment with weekly
gemcitabine (MTD-G) with or without anti-Bv8 antibody (ABv8) administered twice weekly for 2 weeks was initiated. Mouse survival was
assessed. A Kaplan-Meier curve is plotted. *, P b .05; **, .01 N P N .001.
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Plasma from mice treated with the combination of MTD gemcitabine
and anti-Bv8 therapy did not alter the invasion properties of tumor cells
when compared to plasma from gemcitabine-treated mice. Of note,
plasma from control-untreated or isotype-IgG treated mice did not alter
the invasion properties of the tumor cells (Supplemental Figure 3D).
These results further suggest that anti-Bv8 therapy does not directly
affect tumor cell invasion.
Next, we evaluated the survival of mice bearing Panc-02 tumors
following 2 weeks of treatment with weekly gemcitabine with or
without anti-Bv8 antibodies. As seen in Figure 5B, increased survival
time was observed in mice treated with the combination of MTD
gemcitabine and anti-Bv8 antibodies when compared to all other
treatment groups. Taken together, our results suggest that the anti-Bv8 antibody inhibits host pro-tumorigenic and pro-metastatic effects
induced by weekly gemcitabine therapy by means of delayed primary
tumor growth and increased survival but not through direct effect on
the tumor cell invasion.
Discussion
The treatment of PDA has suffered many failures, and treatment
options are limited. Currently, gemcitabine is considered as the main
treatment modality for PDA along with surgery and radiation. Our
previous studies indicated that gemcitabine chemotherapy administered
in bolus injections induces host pro-angiogenic and pro-metastatic effects,
which in turn contribute to tumor regrowth and metastatic spread [5].
Indeed, in this study, we found that mice bearing orthotopic pancreatic
tumormodels exhibit tumor regrowth and/or resistance to therapy, as well
Neoplasia Vol. 16, No. 6, 2014 Anti-Bv8 Antibody and Metronomic Gemcitabine Hasnis et al. 509as an induction in metastatic spread after receiving the course of MTD
gemcitabine. These tumor regrowth effects were minimized or even
negated by the addition of an MC regimen using the same drug. Tran
Cao et al. have previously shown that metronomic gemcitabine in
combination with the antiangiogenic small molecule tyrosine kinase
inhibitor, sunitinib, can also inhibitmetastasis and increase survival rate of
mice bearing PDAs, suggesting that such treatment modality can be used
against PDA in the adjuvant setting [8]. To uncover the possible cellular
mechanism(s) accounting for the tumor regrowth effects, we focused on
MDSCs. Previous studies reported that the levels of MDSCs rise in
peripheral blood in correlation with the development of spontaneous
pancreatic tumors from EL-TFG-α/P53−/− genetically engineered mice.
It has been suggested that the colonization of MDSCs in the pancreatic
tumors inhibits immune cells such asT-cells, which are responsible for the
suppression of tumor growth by the secretion of interferon-γ (IFN-γ)
[28]. Clinically, MDSCs were evaluated in PDA patients in both bone
marrow and peripheral blood, and their levels correlated with disease
stage [29]. In the current study, MDSCs were shown to mobilize and
subsequently home to the treated tumor sites at baseline, an effect that
was dramatically pronounced followingMTDbut notMCgemcitabine
regimen. Thus, MDSCs may account not only for pancreatic tumor
development and growth but also for tumor regrowth following acute
MTD gemcitabine. In contrast, when MC was combined with MTD
gemcitabine, the levels of MDSCs were markedly reduced resulting in a
significant improvement in therapy outcome, both at the primary
tumor level and the metastatic stage.
This study is not the first to show that the combination of MTD
chemotherapy followed by MC regimen improves clinical outcome in
various tumor models [17,20,30]. However, it provides a suitable
explanation as to why these drug regimen combinations are effective. It
was recently reported that the chemo-switch regimen, i.e., MTD
followed by MC regimen, inhibited the proliferation and survival of
cancer stem cells – a subpopulation of tumor cells possessing stem cell
characteristics such as resistance to conventional therapy [20,31]. In
addition, it has also been suggested that MC regimen blocks the
rebound angiogenesis and vasculogenesis effects found at the drug-free
break periods during the course of the MTD regimen. The use of
maintenance MC therapy at times of drug-free breaks suppresses the
levels of circulating endothelial progenitor cells and, hence, inhibits
systemic angiogenesis [11]. Other studies have offered other explana-
tions for the impact ofMC gemcitabine on pancreatic tumor growth. It
has been postulated that MC gemcitabine inhibits T-regulatory cell
homing and retention at the tumor site, as well as suppresses CD8+ T
effector cells, thereby inhibiting tumor regrowth [7,29]. We therefore
assume that the suppression of MDSC colonization of tumors in the
combined treatment regimen group reported in this study improved
therapy outcome by increasing the immune T effector cells against
the tumor. Indeed, the selective depletion of the MDSC subset,
which was found to colonize a genetically engineered mouse model of
PDA, has been shown to induce the accumulation of activated CD8
T cells and to remodel tumor stroma [32]. However, in our PDA
orthotopic model in SCID mice, anti-Bv8 treatment also exhibited
anti-tumor activity. These activities cannot be explained by the role
of MDSCs as immune modulating cells but rather through their
other roles as pro-angiogenic cells [15,33]. Taken together, blocking
MDSCs may affect in various mechanisms on the tumor stroma,
leading to inhibition in tumor growth.
Antiangiogenic drug therapy has been shown to have little or no
effect in PDAs [13]. We therefore initially postulated that the use ofanti-Bv8, a drug with antiangiogenic properties [34,35], would be
ineffective in treating PDAs.However, on the basis of the fact that PDA
regrowth following MTD gemcitabine involves MDSCs, the addition
of anti-Bv8 effectively inhibited tumor growth by inhibiting the
mobilization and tumor homing of MDSCs found following MTD
chemotherapy. It was surprising, however, that such treatment as a
single agent therapy also significantly inhibited PDA tumor growth.We
assume that the inhibition of MDSCs, which may play a critical role in
such tumors, accounts for the tumor growth control in anti-Bv8
monotherapy. Curtis et al. have already reported that anti-Bv8
suppresses angiogenesis in pancreatic tumors [34]. The remaining
question is therefore whether anti-Bv8 in combination with MC
gemcitabine regimen can also improve therapy outcome. Although we
did not address this question in our study, it has been recently indicated
that anti-VEGF therapy blocks the activity of MC therapy by altering
the anti-tumor immune response including the activity and retention of
Natural Killer (NK) cells, macrophages, and dendritic cells at the tumor
site [36]. In addition, sunitinib has also been shown to be effective in
combination with MC gemcitabine using orthotopic models of PDAs
[8]. Thus, anti-Bv8 may counteract the MC gemcitabine regimen, an
effect that is not necessarily related to the antiangiogenic activity of this
drug combination. It would be of interest to use additional
methodologies to comprehensively study the cross-talk between host
and tumor cells and the microenvironment of pancreatic tumors
following treatment with the different regimens. Hoffman et al., in
several studies, have recently shown the development and utilization of a
red fluorescent protein of orthotopic pancreatic cancer model in which
they have evaluated the metastatic properties and the host tumor
cell interactions in tumors following chemotherapy, hence allowing
whole body imaging at the cellular level in living animals and fresh tissues
[37–39]. It is therefore important to evaluate whether anti-Bv8 antibodies
may have other therapeutic activities in tumors besides those related to
angiogenesis and inhibition of MDSC activity by using additional
sophisticated technologies for measuring tumor-host interactions.
Antibody-based therapy in cancer has been extensively used in the
clinic, especially when such drugs are administered as add-on
therapies to conventional treatments. Although therapy outcome is
usually improved in many malignancies, there are some instances
that the therapeutic benefits are relatively modest. This has been an
ongoing discussion regarding the cost-effectiveness of such add-on
drugs [40,41]. In this study, we demonstrate two different add-on
treatments that could be administered in combination with
MTD gemcitabine for the treatment of PDA, both of which have
shown substantial preclinical therapeutic benefit. Although anti-Bv8
antibodies clearly improved the therapy outcome of MTD
gemcitabine, their benefit in the clinical setting is currently
unknown. However, MC gemcitabine, or its oral pro-drug,
LY2334737[25], has shown therapeutic benefits when it was
co-administered in combination with MTD gemcitabine. We must
note, however, that the latter caused major toxicities that may or may
not preclude the use of this combination regimen in the clinic. Yet, the
combined regimen showed remarkable anti-tumor activity when
compared to the conventional MTD gemcitabine regimen. Clinical
evaluation of these two offered treatment modalities in PDAs is
therefore worthy.
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